AVITA Medical, Inc. Australian S.E.

Equities

AVH

AU000000AVH4

Biotechnology & Medical Research

Delayed Australian S.E. 08:41:42 2024-04-17 pm EDT 5-day change 1st Jan Change
3 AUD -2.91% Intraday chart for AVITA Medical, Inc. -24.62% -30.07%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Wilsons Downgrades Avita Medical to Market-Weight From Overweight; Price Target is AU$3.03 MT
BTIG Research Downgrades Avita Medical to Neutral From Buy MT
Avita Medical Lowers Q1 Revenue Guidance on Slower New Account Approvals MT
AVITA Medical, Inc. Revises Revenue Guidance for the First Quarter Ended March 31, 2024 and Full Year Fiscal 2024 CI
AVITA Medical, Inc.(ASX:AVH) added to S&P/ASX All Ordinaries Index CI
AVITA Medical, Inc.(NasdaqCM:RCEL) added to S&P Biotechnology Select Industry Index CI
AVITA Medical Submits Additional RECELL GO PMA Supplement Information to US FDA MT
Transcript : AVITA Medical, Inc. - Special Call
Piper Sandler Raises Price Target on Avita Medical to $21 From $19, Maintains Overweight Rating MT
Transcript : AVITA Medical, Inc., Q4 2023 Earnings Call, Feb 22, 2024
AVITA Medical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
AVITA Medical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
AVITA Medical, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024 CI
Cantor Fitzgerald Adjusts Price Target on Avita Medical to $22 From $20, Maintains Overweight Rating MT
Transcript : AVITA Medical, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 11:15 AM
Sector Update: Health Care Stocks Softer Thursday Afternoon MT
Sector Update: Health Care Stocks Mixed Premarket Thursday MT
Sector Update: Health Care MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday on Expected Rate Cut Trajectory Insights MT
Avita Medical Signs US Distribution Agreement for Wound Healing Products MT
Avita Medical Signs Deal with Stedical Scientific for US Distribution of PermeaDerm MT
AVITA Medical Announces Exclusive Distribution Agreement with Stedical Scientific CI
Avita Medical, Inc. Provides Preliminary Revenue Guidance for Fourth Quarter and Full-Year 2023 and First Quarter and Year 2024 CI
Transcript : AVITA Medical, Inc. - Special Call
Sector Update: Health Care Stocks Rise Tuesday Afternoon MT
Chart AVITA Medical, Inc.
More charts
AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
14.61 AUD
Average target price
41.12 AUD
Spread / Average Target
+181.41%
Consensus
  1. Stock Market
  2. Equities
  3. RCEL Stock
  4. AVH Stock
  5. News AVITA Medical, Inc.
  6. Avita Medical Completes Enrollment in Soft-Tissue Reconstruction Study